Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $26.80 and traded as high as $29.27. Capricor Therapeutics shares last traded at $27.77, with a volume of 745,376 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CAPR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. iA Financial set a $48.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Finally, B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Price Performance

The stock’s 50-day moving average price is $27.04 and its 200 day moving average price is $18.74. The firm has a market cap of $1.73 billion, a P/E ratio of -13.33 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. Suvretta Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $43,516,000. Darwin Global Management Ltd. bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at $23,168,000. Finally, SB Capital Management Inc bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at $11,544,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.